Реферат: Такролимус
Hyperkalemia and hypomagnesemia have occurred in patients receiving Prograf therapy. Hyperglycemia has been noted in many patients; some may require insulin therapy (see WARNINGS).
The incidence of adverse events was determined in two randomized comparative liver transplant trials among 514 patients receiving tacrolimus and steroids and 515 patients receiving a cyclosporine-based regimen (CBIR). The proportion of patients reporting more than one adverse event was 99.8% in the tacrolimus group and 99.6% in the CBIR group. Precautions must be taken when comparing the incidence of adverse events in the U.S. study to that in the European study. The 12-month posttransplant information from the U.S. study and from the European study is presented below. The two studies also included different patient populations and patients were treated with immunosuppressive regimens of differing intensities. Adverse events reported in > 15% in tacrolimus patients (combined study results) are presented below for the two controlled trials in liver transplantation:
LIVER TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN > 15% OF PROGRAF-TREATED PATIENTS
U.S. STUDY (%) | EUROPEAN STUDY (%) | |||||
Prograf |
CBIR |
Prograf |
CBIR |
|||
Nervous System |
||||||
Headache (see WARNINGS) |
64 | 60 | 37 | 26 | ||
Tremor (see WARNINGS) |
56 | 46 | 48 | 32 | ||
Insomnia | 64 | 68 | 32 | 23 | ||
Paresthesia | 40 | 30 | 17 | 17 | ||
Gastrointestinal |
||||||
Diarrhea | 72 | 47 | 37 | 27 | ||
Nausea | 46 | 37 | 32 | 27 | ||
Constipation | 24 | 27 | 23 | 21 | ||
LFT Abnormal | 36 | 30 | 6 | 5 | ||
Anorexia | 34 | 24 | 7 | 5 | ||
Vomiting | 27 | 15 | 14 | 11 | ||
Cardiovascular |
||||||
Hypertension (see PRECAUTIONS) |
47 | 56 | 38 | 43 | ||
Urogenital |
||||||
Kidney Function Abnormal (see WARNINGS) |
40 | 27 | 36 | 23 | ||
Creatinine Increased (see WARNINGS) |
39 | 25 | 24 | 19 | ||
BUN Increased (see WARNINGS) |
30 | 22 | 12 | 9 | ||
Urinary Tract Infection | 16 | 18 | 21 | 19 | ||
Oliguria | 18 | 15 | 19 | 12 | ||
Metabolic and Nutritional |
||||||
Hyperkalemia (see WARNINGS) |
45 | 26 | 13 | 9 | ||
Hypokalemia | 29 | 34 | 13 | 16 | ||
Hyperglycemia (see WARNINGS) |
47 | 38 | 33 | 22 | ||
Hypomagnesemia | 48 | 45 | 16 | 9 | ||
Hemic and Lymphatic |
||||||
Anemia | 47 | 38 | 5 | 1 | ||
Leukocytosis | 32 | 26 | 8 | 8 | ||
Thrombocytopenia | 24 | 20 | 14 | 19 | ||
Miscellaneous |
||||||
Abdominal Pain | 59 | 54 | 29 | 22 | ||
Pain | 63 | 57 | 24 | 22 | ||
Fever | 48 | 56 | 19 | 22 | ||
Asthenia | 52 | 48 | 11 | 7 | ||
Back Pain | 30 | 29 | 17 | 17 | ||
Ascites | 27 | 22 | 7 | 8 | ||
Peripheral Edema | 26 | 26 | 12 | 14 | ||
Respiratory System |
||||||
Pleural Effusion | 30 | 32 | 36 | 35 | ||
Atelectasis | 28 | 30 | 5 | 4 | ||
Dyspnea | 29 | 23 | 5 | 4 | ||
Skin and Appendages |
||||||
Pruritus | 36 | 20 | 15 | 7 | ||
Rash | 24 | 19 | 10 | 4 | ||
Less frequently observed adverse reactions in both liver transplantation and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions below.
Kidney Transplantation
The most common adverse reactions reported were infection, tremor, hypertension, decreased renal function, constipation, diarrhea, headache, abdominal pain and insomnia.
Adverse events that occurred in > 15 % of Prograf-treated kidney transplant patients are presented below:
KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN > 15% OF PROGRAF-TREATED PATIENTS
Prograf |
CBIR |
|
Nervous System |
||
Tremor (see WARNINGS) |
54 | 34 |
Headache (see WARNINGS) |
44 | 38 |
Insomnia | 32 | 30 |
Paresthesia | 23 | 16 |
Dizziness | 19 | 16 |
Gastrointestinal |
||
Diarrhea | 44 | 41 |
Nausea | 38 | 36 |
Constipation | 35 | 43 |
Vomiting | 29 | 23 |
Dyspepsia | 28 | 20 |
Cardiovascular |
||
Hypertension (see PRECAUTIONS) |
50 | 52 |
Chest Pain | 19 | 13 |
Urogenital |
||
Creatinine Increased (see WARNINGS) |
45 | 42 |
Urinary Tract Infection | 34 | 35 |
Metabolic and Nutritional |
||
Hypophosphatemia | 49 | 53 |
Hypomagnesemia | 34 | 17 |
Hyperlipemia | 31 | 38 |
Hyperkalemia (see WARNINGS) |
31 | 32 |
Diabetes Mellitus (see WARNINGS) |
24 | 9 |
Hypokalemia | 22 | 25 |
Hyperglycemia (see WARNINGS) |
22 | 16 |
Edema | 18 | 19 |
Hemic and Lymphatic |
||
Anemia | 30 | 24 |
Leukopenia | 15 | 17 |
Miscellaneous |
||
Infection | 45 | 49 |
Peripheral Edema | 36 | 48 |
Asthenia | 34 | 30 |
Abdominal Pain | 33 | 31 |
Pain | 32 | 30 |
Fever | 29 | 29 |
Back Pain | 24 | 20 |
Respiratory System |
||
Dyspnea | 22 | 18 |
Cough Increased | 18 | 15 |
Musculoskeletal |
||
Arthralgia | 25 | 24 |
Skin |
||
Rash | 17 | 12 |
Pruritis | 15 | 7 |
Less frequently observed adverse reactions in both liver transplantion and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions shown below.
Less Frequently Reported Adverse Reactions
The following adverse events were reported in the range of 3% to less than 15% incidence in either liver or kidney transplant recipients who were treated with tacrolimus in the Phase 3 comparative trials.
NERVOUS SYSTEM: (see WARNINGS) abnormal dreams, agitation, amnesia, anxiety, confusion, convulsion, depression, dizziness, emotional lability, encephalopathy, hallucinations, hypertonia, incoordination, myoclonus, nervousness, neuropathy, psychosis, somnolence, thinking abnormal; SPECIAL SENSES: abnormal vision, amblyopia, ear pain, otitis media, tinnitus; GASTROINTESTINAL: anorexia, cholangitis, cholestatic jaundice, dyspepsia, dysphagia, esophagitis, flatulence, gastritis, gastrointestinal hemorrhage, GGT increase, GI perforation, hepatitis, ileus, increased appetite, jaundice, liver damage, liver function test abnormal, oral moniliasis, rectal disorder, stomatitis; CARDIOVASCULAR: angina pectoris, chest pain, deep thrombophlebitis, abnormal ECG, hemorrhage, hypotension, postural hypotension, peripheral vascular disorder, phlebitis, tachycardia, thrombosis, vasodilatation; UROGENITAL: (see WARNINGS) albuminuria, cystitis, dysuria, hematuria, hydronephrosis, kidney failure, kidney tubular necrosis, nocturia, pyuria, toxic nephropathy, oliguria, urinary frequency, urinary incontinence, vaginitis; METABOLIC/NUTRITIONAL: acidosis, alkaline phosphatase increased, alkalosis, ALT (SGPT) increased, AST (SGOT) increased, bicarbonate decreased, bilirubinemia, BUN increased, dehydration, GGT increased, healing abnormal, hypercalcemia, hypercholesterolemia, hyperlipemia, hyperphosphatemia, hyperuricemia, hypervolemia, hypocalcemia, hypoglycemia, hyponatremia, hypophosphatemia, hypoproteinemia, lactic dehydrogenase increase, weight gain; ENDOCRINE: (see PRECAUTIONS) Cushing's syndrome, diabetes mellitus; HEMIC/LYMPHATIC: coagulation disorder, ecchymosis, hypochromic anemia, leukocytosis, leukopenia, polycythemia, prothrombin decreased, serum iron decreased, thrombocytopenia; MISCELLANEOUS: abdomen enlarged, abscess, accidental injury, allergic reaction, cellulitis, chills, flu syndrome, generalized edema, hernia, peritonitis, photosensitivity reaction, sepsis; MUSCULOSKELETAL: arthralgia, cramps, generalized spasm, joint disorder, leg cramps, myalgia, myasthenia, osteoporosis; RESPIRATORY: asthma, bronchitis, cough increased, lung disorder, pneumothorax, pulmonary edema, pharyngitis, pneumonia, respiratory disorder, rhinitis, sinusitis, voice alteration; SKIN: acne, alopecia, exfoliative dermatitis, fungal dermatitis, herpes simplex, hirsutism, skin discoloration, skin disorder, skin ulcer, sweating.